Home > Healthcare & Medical Devices > Stem Cell Therapy Market
Industry Trends
Stem Cell Therapy Market size surpassed USD 8.9 billion in 2020 and is expected to witness growth rate of over 10.6% from 2021 to 2027. Constant government support and initiatives for research and development activities of regenerative medicine in developed areas is likely to drive the industry demand. For instance, according to the government of Australia, the Medical Research Future Fund’s (MRFF) announced Stem Cell Therapies Mission as a part of the 2019-20 budget. The government funded nearly USD 150 million for research and development of safe and effective treatments accessible to all diseased population.
Get more details on this report - Request Free Sample PDF
The global spread of COVID-19 infection did not have material effect on the industry. Various research institutes and government organizations across the regions were focusing on rapid and effective technologies for the treatment of life-threatening diseases including COVID-19 outbreak. Moreover, several clinical trials were begun with respective to regenerative medicine. However, it is in the initial stage of study in relation to the various different single umbilical cord stem cell market studied.
Report Coverage | Details |
---|---|
Base Year: | 2020 |
Market Size in 2020: | USD 8,898.5 Million |
Forecast Period: | 2021 to 2027 |
Forecast Period 2021 to 2027 CAGR: | 10.6% |
2027 Value Projection: | USD 18,674.7 Million |
Historical Data for: | 2016 to 2020 |
No. of Pages: | 110 |
Tables, Charts & Figures: | 104 |
Segments covered: | Type, Therapeutic Area, End-use and Region |
Growth Drivers: |
|
Pitfalls & Challenges: |
|
Get more details on this report - Request Free Sample PDF
Rising prevalence of rare genetic diseases
Increasing prevalence of rare genetic diseases is anticipated to augment the stem cell therapy market growth. Every year, millions of people suffer from rare diseases such as thalasemmia, phenylketonuria, cystic fibrosis and others. For instance, according to the Firstpost report, in 2020, there were 40 million carriers of thalasemmia in India, which represent one in eight of thalassemia carriers in India. Therefore, conventional therapies and medications have proven less effective in curing these diseases and thus, individuals have now started preferring advanced stem cell therapies that should elevate the industry statistics. Furthermore, advances in stem cell therapies that improve recovery speed in patients suffering from malignancies is expected to boost demand.
Ethical issues associated with stem cell therapy may slow the market
Several safety and ethical issues are associated with the use of stem cells, as these stem cells are derived from the human embryo, thereby limiting the development of human embryonic stem cell (hESC). Additionally, deriving pluripotent stem cell lines from embryos and oocytes is an intense topic of disputes. Medical risks associated with the oocyte retrieval and several other risks related to experimental interventions may impact the demand for stem cell therapies negatively.
Autologous stem cell process is tedious and time consuming
Autologous stem cell therapy segment is projected to grow at around 10.5% through 2027. The autologous stem cell therapy provides high compatibility with human’s immune system, as the patients are their own donors of stem cell. Similarly, the risk of graft rejection is less and the possibilities of using these cells without undergoing clinical trial is poised to spur the market revenue. However, these stem cells require tremendous degree of manipulation and may even need gene modification. Hence, the overall process is tedious and time consuming that may lower the pace of segmental growth.
High success rate of stem cell therapies in treatment of various form of cancer
Get more details on this report - Request Free Sample PDF
Oncology segment accounted for about 37.1% of the stem cell therapy market share in 2020 and is predicted to observe similar trends through 2027. Increasing prevalence of cancer cases coupled with high success rate of stem cell therapies in treatment of cancer is propelling the market expansion. For instance, as per the Memorial Sloan Kettering Cancer Center, the predicted rate of one-year survival for patients undergoing an allogeneic bone marrow transplantation was more than 60%.
Hospitals are collaborating with research institute to upgrade its treatment offering
Hospitals end-use segment is estimated to register nearly 10.6% gains till 2027. Growing preference for stem cell therapies provided in hospitals to avoid complications caused owing to the invasive methods including surgical procedures is spurring the industry size. Currently, hospitals are affiliated with research laboratories and academic institutes that conducts extensive research for the development of innovative stem cell therapies. Collaborations with research institutes allow hospitals to upgrade its treatment offerings, thereby, positively influence the market statistics.
High favorable government activities in North America
Get more details on this report - Request Free Sample PDF
North America stem cell therapy market valued at USD 3.7 billion in 2020 and is forecast to expand at 10.3% CAGR from 2021 to 2027. Considerable regional growth can be attributed to the favourable government initiatives. For instance, in November 2020, government of Canada and JDRF Canada announced a new research funding of USD 6 million to accelerate stem cell-based therapies for type 1 diabetes. In addition, technological advancements in regenerative medicine will further support the market demand.
Growth strategies of market players are focused on increasing the customer base
Few of the notable stem cell therapy market players are Astellas Pharma Inc, Novadip Biosciences, MEDIPOST, Fujifilm Cellular Dynamics, DiscGenics, Mesoblast Ltd and Takeda Pharmaceutical among others. Companies adopt strategies such as novel product launch, mergers and acquisitions to foster business.
Recent industry developments:
- In March 2021, Novadip Biosciences received approval from U.S. FDA for the Company’s Investigational New Drug (IND) application for its autologous cell therapy product NVD-003. The product is used for the treatment of Congenital Pseudarthrosis of the Tibia (CPT). This strategy is likely to enhance their product offerings and expand their customer base, thereby strengthening its market position.
- In January 2020, Astellas Pharma Inc. entered into the licensing agreement with Allele Biotechnology and Pharmaceuticals, Inc., a company engaged in the development of cell-based therapeutics. This agreement aimed at expanding Astellas access to Allele’s induced pluripotent stem cell (iPSC) technologies for various cell therapy. This strategy enabled company to offer innovative solution as well as maintain its long-term business relation.
This stem cell therapy market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2016 to 2027, for the following segments
Market, By Type
- Allogenic stem cell therapy
- Autologous stem cell therapy
Market, By Therapeutic Area
- Oncology
- Orthopedic
- Cardiovascular
- Neurology
- Others
Market, By End-use
- Hospitals
- Clinics
- Others
The above information is provided for the following regions and countries:
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Russia
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East and Africa
- South Africa
- Saudi Arabia
- UAE
Frequently Asked Questions (FAQ) :